Curative Biotechnology stock analysis
Curative Biotechnology (CUBT) Stock Price & Analysis
CUBT Stock Chart & Stats
- Day’s Range
- $0.70 - $0.85
- 52-Week Range
- $0.03 - $5.00
- Previous Close
- $0.81
- Volume
- N/A
- Average Volume (3M)
- 1,514
- Market Cap
- $5.80M
- Enterprise Value
- $10.21T
- Total Cash (Recent Filing)
- $145.26K
- Total Debt (Recent Filing)
- $1.36M
- Price to Earnings (P/E)
- ―
- Beta
- -1.18
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Curative Biotechnology News
Curative Biotech announces completion of IND enabling HCL eye drop study
Curative Biotechnology announced that it has successfully completed its Investigational New Drug, IND, enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation in Rabbits. Paul Michaels, Chairman
CUBT FAQ
What was Curative Biotechnology’s price range in the past 12 months?
What is Curative Biotechnology’s market cap?
When is Curative Biotechnology’s upcoming earnings report date?
How were Curative Biotechnology’s earnings last quarter?
Is Curative Biotechnology overvalued?
Does Curative Biotechnology pay dividends?
What is Curative Biotechnology’s EPS estimate?
How many shares outstanding does Curative Biotechnology have?
What happened to Curative Biotechnology’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Curative Biotechnology?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Curative Biotechnology
Curative Biotechnology, Inc. is an emerging biomedical firm primarily focused on developing pharmaceutical products. Its research and development efforts are concentrated on a diverse pipeline targeting critical therapeutic areas, including infectious diseases, cancer, and vision-impairing degenerative eye conditions. Among its key pipeline assets is IMT504, an innovative immunotherapy designed for rabies treatment and as a vaccine enhancer. Another prominent candidate is CUBT906, a fully humanized CD56 monoclonal antibody that delivers a pyrrolobenzodiazepine dimer directly to tumor cells, aiming to eradicate them by halting their growth and spread. Additionally, the company is advancing a reformulated Metformin for the management of degenerative eye disorders. Curative Biotechnology has entered into a licensing and co-development partnership with Mid-Atlantic BioTherapeutics, Inc. to further advance IMT504, specifically for addressing advanced rabies and as a component of a COVID-19 vaccine. Previously known as Connectyx Technologies Holdings Group, Inc., the company adopted its current name, Curative Biotechnology, Inc., in November 2020. Established in 1995, the company maintains its headquarters in Boca Raton, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- I. Richard Garr
- Employees
- 4
- Website
- curativebiotech.com
- Address
- 3801 PGA Blvd Suite 600, Palm Beach Gardens, FL, 33410, US
Curative Biotechnology (CUBT) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 2 | 8 |
| Technical Analysis | 3 | 2 | 4 |
| Moving Averages | 6 | 0 | 4 |






